A phase 2 trial shows significant reduction in drinks per drinking day and weekly alcohol craving with low-dose semaglutide. HealthDay News — Low-dose semaglutide seems to reduce craving and certain ...

Fact checked by Nick Blackmer “Microdosing” GLP-1 drugs like Ozempic is gaining attention on social media, but doctors say it ...

Microcap Allurion Technologies (NYSE:ALUR) surged ~31% in after-hours trading Thursday after posting preliminary data on ...

Semaglutide shows promise in reducing alcohol cravings and consumption. Could it be a future treatment for AUD?

Last month, the U.S. Food and Drug Administration (the “FDA”) announced in a Declaratory Order the resolution of the shortage of semaglutide ...

Ozempic (semaglutide) is prescribed for adults with ... used for starting and maintenance dosages 0.25 mg, given for 4 weeks 0.5 mg, given after 4 weeks of the starting dose once per week, any ...

Ozempic (semaglutide) helps manage blood sugar levels, lowers cardiovascular risks, and treats chronic kidney disease (CKD). Ozempic is a solution given as a subcutaneous injection. Dosages can ...

Vivani Medical completed enrollment in its LIBERATE-1 trial, testing a six-month GLP-1 implant for weight management.

There is initial evidence that low-dose semaglutide may reduce craving and drinking outcomes in individuals with alcohol-use disorder.

Now that the shortage of semaglutide injection products has been resolved, the Food and Drug Administration (FDA) will restrict third parties ...

The researchers found that low-dose semaglutide (0.25 mg/week for 4 weeks, 0.5 mg/week for 4 weeks, and 1 mg for one week) reduced the amount of alcohol consumed during a posttreatment laboratory ...

Patients were then started on 0.25 mg semaglutide which was increased to a maximum of 1.0mg over the next six months. At eight months of receiving combination treatment, average total body weight ...